The role of CYP1A1 genotype in lung cancer risk was assessed in African Americans through a case control study. The complete CYP1A1 genotype, including the frequency of all three polymorphisms (Msp1 [CYP1A1*2], exon 7 [CYP1A1*3] and African American specific [CYP1A1*4]) was determined by PCR on 307 controls and 105 cases of lung cancer among African Americans. We have confirmed our earlier observation of a significant increased risk (odds ratio = 2.8, 95% CI = 1.3-6.5) for lung adenocarcinoma among people with the *4 polymorphism, although we did not observe any association of this polymorphism with overall lung cancer risk. As previously reported, we found that lung adenocarcinoma patients with the *4 RFLP smoked significantly less than patients without this polymorphism, suggesting an important role in cancer risk of low exposure levels to cigarette smoke in subjects carrying susceptibility polymorphisms. There was no association with the other two polymorphisms and lung cancer in this population. When we examined lung cancer risk as a function of composite genotype, taking into account all three polymorphisms simultaneously in each subject, our preliminary data suggested an association of one rare genotype (homozygous Msp1, heterozygous exon 7 or *2/*2*3) with overall lung cancer risk (OR = 8.4, 95% CI = 1.6-43.2).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/carcin/19.5.813 | DOI Listing |
Cancer Nurs
January 2025
Author Affiliations: Departments of Physiotherapy (Drs Heredia Ciuró, Martín Núñez, Navas Otero, Calvache Mateo, Torres Sánchez, and Valenza) and Nursing (Dr Granados Santiago), Faculty of Health Sciences, University of Granada, Granada, Spain.
Background: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness.
View Article and Find Full Text PDFCurr Oncol Rep
January 2025
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.
Purpose Of Review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC.
View Article and Find Full Text PDFChem Biodivers
January 2025
Jiangxi University of Chinese Medicine, Research Center for Differentiation and Development of CM Basic Theory of Jiangxi University of Chinese Medicine, Jiangxi Province Key Laboratory of CM Etiopathogenesis, Nanchang, Jiangxi, China, 330004, 330004, nan chang, CHINA.
Qingzao Jiufei Decoction (QD) is a renowned prescription for nourishing lung Yin to treat lung related diseases in ancient and modern times. It has been reported that QD can effectively inhibit the growth of lung cancer, but the material basis and mechanism of its treatment of LC remain to be further studied. In this experiment, we combined serum pharmacochemistry and proteomics to study the pharmacodynamic material basis and mechanism of QD against lung cancer.
View Article and Find Full Text PDFMacromol Biosci
January 2025
Department of Pediatrics, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03030, Türkiye.
Chemotherapy is generally given by intravenous (IV) administration which provides higher bioavailability than other systemic routes. However, in the case of lung cancer, the pulmonary (INH) route is the other choice for inhalable formulations. In the study, biochemical and histological parameters of Cabazitaxel (CBZ) free (2 mg kg) and nanoparticle (NP) (2 mg kg CBZ equivalent) formulations are investigated after IV and INH administration in rats.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!